REVVITY, INC.

Previous wording

•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health and emerging market diagnostics.

Current wording

•Diagnostics. Develops diagnostics, tools and applications focused on clinically-oriented customers, especially within the areas of reproductive health, immunodiagnostics and emerging market diagnostics.

Previous wording

Overview of the First Quarter of Fiscal Year 2026

Current wording

Overview of the Second Quarter of Fiscal Year 2026

Previous wording

Our overall revenue in the first quarter of fiscal year 2026 was $711.1 million which increased by $46.4 million, or 7%, as compared to the first quarter of fiscal year 2025, reflecting an increase of $24.9 million, or 8%, in our Diagnostics segment revenue, and an increase of $21.4 million, or 6%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the first quarter of fiscal year 2026 was driven by both our Reproductive Health business and favorable changes in foreign exchange rates. The increase in our Life Sciences segment revenue for the first quarter of fiscal year 2026 was driven by both our Life Sciences Solutions and Software businesses and the extra fiscal week.

Current wording

Our overall revenue in the second quarter of fiscal year 2026 was $729.7 million which increased by $9.4 million, or 1%, as compared to the second quarter of fiscal year 2025, reflecting an increase of $16.6 million, or 5%, in our Diagnostics segment revenue, and a decrease of $7.2 million, or 2%, in our Life Sciences segment revenue. The increase in our Diagnostics segment revenue for the second quarter of fiscal year 2026 was driven by both our Reproductive Health business and favorable changes in foreign exchange rates. The decrease in our Life Sciences segment revenue for the second quarter of fiscal year 2026 was driven by a decline in revenue in our Software business.

Previous wording

Our consolidated gross margins decreased 200 basis points from 56.5% to 54.5% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week. Our consolidated operating margins decreased from 10.9% to 10.7% in the first quarter of fiscal year 2026, as compared to the first quarter of fiscal year 2025, primarily due to gross margin headwinds and impact of the extra fiscal week, partially offset by productivity and cost containment initiatives.

Current wording

Our consolidated gross margins increased 260 basis points from 54.5% to 57.1% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to tariff refunds and product mix shift. Our consolidated operating margins decreased from 12.6% to 12.2% in the second quarter of fiscal year 2026, as compared to the second quarter of fiscal year 2025, primarily due to restructuring charges and digital investments.

Previous wording

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to accounting for business combinations, divestitures, long-lived assets, including goodwill and other intangible assets, and employee compensation and benefits. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Current wording

The preparation of condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Previous wording

Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include policies regarding business combinations, divestitures, valuation of long-lived assets, including goodwill and other intangibles and employee compensation and benefits.

Current wording

Critical accounting policies are those policies that affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements. We believe our critical accounting policies include policies regarding valuation of goodwill and income taxes.

Previous wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the three months ended April 5, 2026.

Current wording

For a more detailed discussion of our critical accounting policies and estimates, refer to the Notes to our audited consolidated financial statements and Item 7.“Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended December 28, 2025 (our “2025 Form 10-K”), as filed with the Securities and Exchange Commission. There have been no significant changes in our critical accounting policies and estimates during the six months ended July 5, 2026.

Previous wording

Revenue for the three months ended April 5, 2026 was $711.1 million, as compared to $664.8 million for the three months ended March 30, 2025, an increase of $46.4 million, or 7%, which includesa 3% increase in revenue attributable to favorable changes in foreign exchange rates and a 1%increase in revenue attributable to acquisitions. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $361.8 million for the three months ended April 5, 2026, as compared to $340.4 million for the three months ended March 30, 2025, an increase of $21.4 million, or 6%, driven by an increase of $13.5 million in Life Sciences Solutions revenue and an increase of $7.9 million in Software revenue and the extra fiscal week. Diagnostics segment revenue was $349.3 million for the three months ended April 5, 2026, as compared to $324.4 million for the three months ended March 30, 2025, an increase of $24.9 million, or 8%, due to an increase of $20.6 million in Reproductive Health revenue and an increase of $4.3 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended July 5, 2026 was $729.7 million, as compared to $720.3 million for the three months ended June 29, 2025, an increase of $9.4 million, or 1%. The analysis in the remainder of this paragraph comp ares segment revenue and includes the effect of foreign exchange rate fluctuations. Life Sciences segment revenue was $358.7 million for the three months ended July 5, 2026, as compared to $365.9 million for the three months ended June 29, 2025, a decrease of $7.2 million, or 2%, driven by a decrease of $10.2 million in Software revenue, partially offset by an increase of $3.0 million in Life Sciences Solutions revenue. Diagnostics segment revenue was $371.0 million for the three months ended July 5, 2026, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%, due to an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue.

Previous wording

Cost of revenue for the three months ended April 5, 2026 was $323.5 million, as compared to $289.2 million for the three months ended March 30, 2025, an increase of $34.2 million, or 12%. As a percentage of revenue, cost of revenue increased to 45.5% for the three months ended April 5, 2026, from 43.5% for the three months ended March 30, 2025, resulting in a decrease in gross margin of 200 basis points to 54.5% for the three months ended April 5, 2026, from 56.5% for the three months ended March 30, 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week. Amortization of intangible assets was $35.0 million for the three months ended April 5, 2026, as compared to $34.4 million for the three months ended March 30, 2025.

Current wording

Cost of revenue for the three months ended July 5, 2026 was $312.8 million, as compared to $327.7 million for the three months ended June 29, 2025, a decrease of $14.9 million, or 5%. As a percentage of revenue, cost of revenue decreased to 42.9% for the three months ended July 5, 2026, from 45.5% for the three months ended June 29, 2025, resulting in an increase in gross margin of 260 basis points to 57.1% for the three months ended July 5, 2026, from 54.5% for the three months ended June 29, 2025, primarily due to tariff refunds and product mix shift. Amortization of intangible assets was $34.8 million for the three months ended July 5, 2026, as compared to $36.5 million for the three months ended June 29, 2025.

Previous wording

Tariffs enacted and currently in effect increased our cost of revenue by approximately $8 million for the three months ended April 5, 2026. Through proactive mitigation efforts, the net impact on gross margin was approximately $6 million for the three months ended April 5, 2026. On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act (“IEEPA”) does not authorize the imposition of tariffs. In March 2026, the U.S. Court of International Trade ordered U.S. Customs and Border Protection (CBP) to finalize or revise certain import duty determinations excluding IEEPA duties. The court then suspended the order to the extent it required immediate action while CBP implemented an administrative refund process. While we intend to seek refunds, the timing and amount of recoveries remain uncertain and will depend on the scope and timing of court or administrative developments and completion of applicable administrative steps. Accordingly, no refund receivable has been recorded as of April 5, 2026.

Current wording

On February 20, 2026, the United States Supreme Court ruled that the International Emergency Economic Powers Act does not authorize the imposition of tariffs. In April 2026, the U.S. Customs and Border Protection (CBP) announced a new administrative process for importers to utilize in seeking to obtain refunds. Through the established CBP refund process, the Company applied for $20.2 million of refunds and received $16.2 million through July 5, 2026. The timing and amount of additional recoveries remain uncertain and will depend on the scope and timing of court or administrative developments and completion of applicable administrative steps. Accordingly, refunds have been recorded in income upon receipt of payment, and no refund receivable has been recorded as of July 5, 2026. As a result, $16.2 million of refunds were recorded in cost of revenue for the three months ended July 5, 2026.

Previous wording

Selling, general and administrative expenses for the three months ended April 5, 2026 were $253.9 million, as compared to $249.7 million for the three months ended March 30, 2025, an increase of $4.2 million, or 2%. As a percentage of revenue, selling, general and administrative expenses decreased and were 35.7% for the three months ended April 5, 2026, as compared to 37.6% for the three months ended March 30, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended April 5, 2026, as compared to $48.3 million for the three months ended March 30, 2025. Restructuring and other costs increased and was $10.7 million for the three months ended April 5, 2026, as compared to $3.2 million for the three months ended March 30, 2025. Restructuring and other costs in the first quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the first quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of our workforce. Transformation costs were $0.8 millionfor the three months ended April 5, 2026. Purchase accounting adjustments decreased expenses by $0.1 million for the three months ended April 5, 2026, which primarily consisted of a change in contingent consideration, as compared to $0.4 million for the three months ended March 30, 2025. Costs for significant environmental matters decreased expenses by $1.2 million for the three months ended March 30, 2025. The above increases were also partially offset by a decrease in significant litigation matters and settlements, which was $0.1 million for the three months ended April 5, 2026, as compared to $10.6 million for the three months ended March 30, 2025. Disposition of businesses and assets, net decreased expenses by $5.1 million for the three months ended April 5, 2026. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, decreased and was $0.3 million for the three months ended April 5, 2026, as compared to $2.5 million for the three months ended March 30, 2025. Excluding the items noted above, selling, general and administrative expenses increased labor costs due to the extra fiscal week in the current quarter as compared to the same period in the prior year and employee incentive compensation.

Current wording

Selling, general and administrative expenses for the three months ended July 5, 2026 were $278.6 million, as compared to $248.5 million for the three months ended June 29, 2025, an increase of $30.1 million, or 12%. As a percentage of revenue, selling, general and administrative expenses increased and were 38.2% for the three months ended July 5, 2026, as compared to 34.5% for the three months ended June 29, 2025. Amortization of intangible assets increased and was $50.1 million for the three months ended July 5, 2026, as compared to $48.8 million for the three months ended June 29, 2025. Restructuring and other costs increased and were $35.5 million for the three months ended July 5, 2026, as compared to $11.2 million for the three months ended June 29, 2025. Restructuring and other costs in the second quarter of fiscal year 2026 primarily consisted of charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, costs of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. In the second quarter of fiscal year 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 3% of our workforce. The above increases were partially offset by a decrease in purchase accounting adjustments, which were $1.7 million for the three months ended July 5, 2026, and primarily consisted of a change in contingent consideration, as compared to $2.0 million for the three months ended June 29, 2025. Acquisition and divestiture-related expenses, which primarily consisted of legal and integration costs, were $0.1 million for the three months ended July 5, 2026, as compared to $1.2 million for the three months ended June 29, 2025. Significant litigation matters and settlements decreased, and were $0.1 million for the three months ended July 5, 2026, as compared to $1.1 million for the three months ended June 29, 2025. Transformation costs were a net credit of $0.7 million for the three months ended July 5, 2026. Excluding the items noted above, selling, general and administrative expenses increased due to digital investments and employee incentive compensation.

Previous wording

Research and development expenses for the three months ended April 5, 2026 were $57.9 million, as compared to $53.6 million for the three months ended March 30, 2025, an increase of $4.3 million, or 8%. As a percentage of revenue, research and development expenses were flat at 8.1% for both the three months ended April 5, 2026 and the three months ended March 30, 2025. The increase in research and development expenses was primarily driven by our investments in new product development and increased labor costs due to the extra fiscal week.

Current wording

Research and development expenses for the three months ended July 5, 2026 were $49.0 million, as compared to $53.3 million for the three months ended June 29, 2025, a decrease of $4.3 million, or 8%. As a percentage of revenue, research and development expenses decreased and were 6.7% for the three months ended July 5, 2026, as compared to 7.4% for the three months ended June 29, 2025. The decrease in research and development expenses was primarily driven by cost containment initiatives.

Previous wording

The decrease in interest income for the three months ended April 5, 2026 as compared to the three months ended March 30, 2025 was primarily due to a decrease in marketable securities and short-term investments. Interest expense was higher for the three months ended April 5, 2026 as compared to the same period in the prior year primarily due to the extra fiscal week in the current quarter, which resulted in one additional week of accrued interest as compared to the quarter ended March 30, 2025.

Current wording

The decrease in interest income for the six months ended July 5, 2026 as compared to the six months ended June 29, 2025 was primarily due to decreases in interest rates and lower cash balances. Interest expense was higher for the six months ended July 5, 2026 as compared to the same period in the prior year primarily due to the extra fiscal week in the first quarter as compared to the same period in the prior year, which resulted in one additional week of accrued interest as compared to the six months ended June 29, 2025.

Previous wording

The provision for income taxes from continuing operations was $9.1 million for the three months ended April 5, 2026, as compared to $10.7 million for the three months ended March 30, 2025.

Current wording

The provision for income taxes from continuing operations was $10.1 million for the three months ended July 5, 2026, as compared to $13.4 million for the three months ended June 29, 2025. The provision for income taxes from continuing operations was $19.1 million for the six months ended July 5, 2026, as compared to $24.1 million for the six months ended June 29, 2025.

Previous wording

The effective tax rate from continuing operations was 18.2% for the three months ended April 5, 2026, as compared to 20.5% for the three months ended March 30, 2025. The effective tax rate for the three months ended April 5, 2026 was lower primarily due to net favorable impacts of prior year true-ups recorded in fiscal year 2026 in foreign locations of $1.0 million as compared to fiscal year 2025. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026.

Current wording

The effective tax rate from continuing operations was 15.8% and 16.9% for the three and six months ended July 5, 2026, as compared to 19.6% and 19.9% for the three and six months ended June 29, 2025. The effective tax rate for the three and six months ended July 5, 2026 was lower as compared to the three and six months ended June 29, 2025 primarily due to favorable impacts related to state deferred tax remeasurements in fiscal year 2026 of $2.4 million. We expect that the effective tax rate on continuing operations, before discrete items, will be approximately 20% during fiscal year 2026.

Previous wording

Segment operating income for the three months ended April 5, 2026 was $104.0 million, as compared to $105.7 million for the three months ended March 30, 2025, a decrease of $1.7 million, or 2%. Segment operating margin decreased 240 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, strategic investments in software and new product development and impact of the extra fiscal week.

Current wording

Segment operating income for the three months ended July 5, 2026 was $111.5 million, as compared to $115.5 million for the three months ended June 29, 2025, a decrease of $3.9 million, or 3%. Segment operating margin decreased 50 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to strategic investments in software and new product development, partially offset by favorable product mix shift.

Previous wording

Revenue for the three months ended April 5, 2026 was $349.3 million, as compared to $324.4 million for the three months ended March 30, 2025, an increase of $24.9 million, or 8%, which includes a 4% increase in revenue attributable to favorable changes in foreign exchange rates. Theincrease in our Diagnostics segment revenue duringthe three months ended April 5, 2026 was driven by an increase of $20.6 million in Reproductive Health revenue and an increase of $4.3 million in Immunodiagnostics revenue.

Current wording

Revenue for the three months ended July 5, 2026 was $371.0 million, as compared to $354.4 million for the three months ended June 29, 2025, an increase of $16.6 million, or 5%. Theincrease in our Diagnostics segment revenue duringthe three months ended July 5, 2026 was driven by an increase of $20.7 million in Reproductive Health revenue, partially offset by a decrease of $4.1 million in Immunodiagnostics revenue.

Previous wording

Segment operating incomefor the three months ended April 5, 2026 was $76.1 million, as compared to $74.0 millionfor the three months ended March 30, 2025, an increase of $2.1 million, or 3%. Segment operating margin decreased 100 basis points in the three months ended April 5, 2026, as compared to the three months ended March 30, 2025, primarily due to product mix shift, changes in foreign exchange rates, increased tariffs and impact of the extra fiscal week.

Current wording

Segment operating incomefor the three months ended July 5, 2026 was $112.9 million, as compared to $89.4 millionfor the three months ended June 29, 2025, an increase of $23.4 million, or 26%. Segment operating margin increased 520 basis points in the three months ended July 5, 2026, as compared to the three months ended June 29, 2025, primarily due to tariff refunds and cost containment initiatives.

Previous wording

At April 5, 2026, we had cash and cash equivalents of$860.3 million, of which $518.3 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Current wording

At July 5, 2026, we had cash and cash equivalents of$1,022.9 million, of which $544.5 million was held by our non-U.S. subsidiaries, and we had$1.5 billion of borrowing capacity available under our senior unsecured revolving credit facility. We use a variety of cash redeployment and financing strategies to ensure that our worldwide cash is available in the locations in which it is needed.

Previous wording

On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for an aggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at anytime. During the three months ended April 5, 2026, we repurchased 784,142 shares of common stock under the Repurchase Program for an aggregate cost of $79.0 million. As of April 5, 2026,$800.5 million remained available for aggregate repurchases ofshares under the Repurchase Program. Subsequent to the first quarter of fiscal year 2026, we repurchased 93,303 shares of common stock under the Repurchase Program at an aggregate cost of $7.8 million. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.

Current wording

On October 23, 2025, our Board of Directors (our “Board”) authorized us to repurchase shares of common stock for anaggregate amount up to $1.0 billion under a stock repurchase program (the “Repurchase Program”). The Repurchase Program will expire on October 22, 2027 unless terminated earlier by our Board and may be suspended or discontinued at anytime. During the three months ended July 5, 2026, we repurchased 93,303 shares of common stock under the Repurchase Program for an aggregate cost of $7.8 million. As of July 5, 2026,$792.7 million remained available for aggregate repurchases ofshares under the Repurchase Program. There have been no share repurchases subsequent to the second quarter of fiscal year 2026. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.

Previous wording

As of April 5, 2026, we may have to pay contingent consideration related to acquisi tions with open contingency periods of up to $81.6 million. As of April 5, 2026, we have recorded contingent consideration obligations of $25.0 million, of which $4.0 million was recorded in accrued expenses and other current liabilities, and $21.0 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.7 years from April 5, 2026, and the remaining weighted average expected earnout period at April 5, 2026 was 3.2 years.

Current wording

As of July 5, 2026, we may have to pay contingent consideration related to acquisi tions with open contingency periods of up to $71.2 million. As of July 5, 2026, we have recorded contingent consideration obligations of $15.4 million, of which $4.0 million was recorded in accrued expenses and other current liabilities, and $11.4 million was recorded in long-term liabilities. The maximum earnout period for acquisitions with open contingency periods is 5.4 years from July 5, 2026, and the remaining weighted average expected earnout period at July 5, 2026 was 3.0 years.

Previous wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $125.9 million for the three months ended April 5, 2026, as compared to $134.1 million for the three months ended March 30, 2025, a decrease of $8.2 million. The cash provided by operating activities for the three months ended April 5, 2026 was principally a result of adjustments for non-cash charges aggregating to $124.7 million, including depreciation and amortization of $105.1 million, income from continuing operations of $40.9 million, and a net cash decrease in working capital of $39.7 million, primarily due to timing of collections, inventory purchases and employee incentive compensation payout. The cash provided by operating activities for the three months ended March 30, 2025 was principally a result of adjustments for non-cash charges aggregating to $105.7 million, including depreciation and amortization of $97.4 million, income from continuing operations of $41.7 million, and a net cash decrease in working capital of $13.3 million.

Current wording

Operating Activities. Net cash provided by operating activities of ourcontinuing operations was $317.8 million for the six months ended July 5, 2026, as compared to $268.4 million for the six months ended June 29, 2025, an increase of $49.4 million. The cash provided by operating activities for the six months ended July 5, 2026 was principally a result of adjustments for non-cash charges aggregating to $281.3 million, including depreciation and amortization of $207.1 million and income from continuing operations of $94.4 million, partially offset by a net cash decrease in working capital of $57.8 million, primarily due to annual employee incentive compensation payout and timing of inventory build and vendor payments, partially offset by robust collections performance. The cash provided by operating activities for the six months ended June 29, 2025 was principally a result of adjustments for non-cash charges aggregating to $233.7 million, including depreciation and amortization of $200.2 million, and income from continuing operations of $96.9 million, partially offset by a net cash decrease in working capital of $62.2 million.

Previous wording

Investing Activities. Net cash used in investing activitiesof our continuing operationswas $78.3 million for the three months ended April 5, 2026, as compared to $15.8 million for the three months ended March 30, 2025, an increase of $62.5 million primarily due to cash paid for acquisitions, net of cash acquired of $67.3 million during the three months ended April 5, 2026. During the three months ended April 5, 2026, net cash used for capital expenditures was $19.8 million, as compared to $16.0 million for the three months ended March 30, 2025. During the three months ended April 5, 2026, purchases of investments and notes receivables were $1.1 million. The cash used in investing activities during the three months ended April 5, 2026 was partially offset by $0.2 million proceeds from disposition of businesses and assets, remaining flat compared to the three months ended March 30, 2025. During the three months ended April 5, 2026, proceeds from disposition of property, plant and equipment amounted to $9.0 million. During the three months ended April 5, 2026, proceeds from investments and notes receivable amounted to $0.7 million.

Current wording

Investing Activities. Net cash used in investing activitiesof our continuing operationswas $81.8 million for the six months ended July 5, 2026, as compared to $34.6 million for the six months ended June 29, 2025, an increase of $47.2 million primarily due to cash paid for acquisitions, net of cash acquired of $67.1 million during the six months ended July 5, 2026. During the six months ended July 5, 2026, net cash used for capital expenditures was $30.8 million, as compared to $34.9 million for the six months ended June 29, 2025. During the six months ended July 5, 2026, purchases of investments and notes receivables were $3.6 million. The cash used in investing activities during the six months ended July 5, 2026 was partially offset by $12.0 million of proceeds from disposition of property, plant and equipment. During the six months ended July 5, 2026, proceeds from investments and notes receivable amounted to $7.5 million. During the six months ended July 5, 2026, proceeds from disposition of businesses and assets amounted to $0.2 million, remaining flat compared to the six months ended June 29, 2025.

Previous wording

Financing Activities. Net cash used in financing activities was $88.9 million for the three months ended April 5, 2026, as compared to $163.7 million for the three months ended March 30, 2025, a decrease of $74.8 million. During the three months ended April 5, 2026, we repurchased shares of our common stock for a total cost of $86.5 million, as compared to $153.6 million in the prior year period. We paid $7.8 million in dividends for the three months ended April 5, 2026, as compared to $8.4 million for the three months ended March 30, 2025. During the three months ended March 30, 2025, we made net payments of$2.5 millionon debts. We paid $1.8 million for acquisition-related contingent consideration during the three months ended March 30, 2025. The cash used in financing activities during the three months ended April 5, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $5.4 million during the three months ended April 5, 2026, as compared to $2.6 million for the three months ended March 30, 2025.

Current wording

Financing Activities. Net cash used in financing activities was $112.1 million for the six months ended July 5, 2026, as compared to $466.1 million for the six months ended June 29, 2025, a decrease of $354.1 million. During the six months ended July 5, 2026, we repurchased shares of our common stock for a total cost of $102.5 million, as compared to $447.5 million in the prior year period. We paid $15.7 million in dividends for the six months ended July 5, 2026, as compared to $16.7 million for the six months ended June 29, 2025. We paid $0.4 million for acquisition-related contingent consideration during the six months ended July 5, 2026, as compared to $2.0 million for the six months ended June 29, 2025. During the six months ended June 29, 2025, we made net payments of$2.6 millionon debts. The cash used in financing activities during the six months ended July 5, 2026 was partially offset by proceeds from the issuance of common stock under our stock plans of $6.4 million during the six months ended July 5, 2026, as compared to $2.6 million for the six months ended June 29, 2025.

Previous wording

Our outstanding€500,000 Principal 1.875% Senior Unsecured Notes due in 2026(the “2026 Notes”) will maturein July 2026. We expect to repay the 2026 Notes with our existing cash on hand or borrowings under our senior unsecured revolving credit facility, or a combination thereof. See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-Kfor a detailed discussion of our borrowing arrangements.

Current wording

Subsequent to the second quarter of fiscal year 2026, we repaid upon maturity all of our outstanding €500,000 Principal 1.875% Senior Unsecured Notes due in 2026 (the “2026 Notes”) at an aggregate principal amount of €500.0 million ($571.2 million). See Note 7, Debt, in the Notes to Condensed Consolidated Financial Statements and Note 13, Debt, to our audited consolidated financial statements in the 2025 Form 10-K for a detailed discussion of our borrowing arrangements.

Previous wording

Our Board declared a regular quarterly cash dividend of $0.07 per share forthe first quarterof fiscal year 2026 and in each quarter of fiscal year 2025. At April 5, 2026, we had accrued $7.8 million for dividends declared on January 26, 2026 for the first quarter of fiscal year 2026 that were paid in May 2026. On April 30, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the second quarter of fiscal year 2026 that will be payable in August 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Current wording

Our Board declared a regular quarterly cash dividend of $0.07 per share for each of the first two quartersof fiscal year 2026 and in each quarter of fiscal year 2025. At July 5, 2026, we had accrued $7.8 million for dividends declared on April 30, 2026 for the second quarter of fiscal year 2026 that were paid in August 2026. On July 31, 2026, we announced that our Board had declared a quarterly dividend of $0.07 per share for the third quarter of fiscal year 2026 that will be payable in November 2026. In the future, our Board may determine to reduce or eliminate our common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Previous wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during the three months ended April 5, 2026.

Current wording

See Note 1, Nature of Operations and Accounting Policies, to our audited consolidated financial statements in the 2025 Form 10-K for a summary of recently adopted new accounting pronouncements during the fiscal year ended December 28, 2025. We have not adopted any new accounting pronouncements during the six months ended July 5, 2026.